Search

Your search keyword '"Ludolph, Albert C."' showing total 17 results
Start Over Author "Ludolph, Albert C." Journal plos one
17 results on '"Ludolph, Albert C."'

1. Screening instruments of cognition: The relation of the mini-mental state examination to the Edinburgh cognitive and behavioural ALS screen in amyotrophic lateral sclerosis.

Author

Serian, Angela, Finsel, Julia, Ludolph, Albert C., Uttner, Ingo, and Lulé, Dorothée

Subjects
MINI-Mental State Examination, MEDICAL screening, AMYOTROPHIC lateral sclerosis, NEUROPSYCHOLOGICAL tests, NONLINEAR regression, COGNITION, COGNITION disorders
Abstract

Objective: The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) is an established cognitive screening instrument for patients with amyotrophic lateral sclerosis (ALS). Different from tools like the Mini-Mental State Examination (MMSE), it is adjusted for motor impairment, yet, the latter remains one of the most widely used screening instruments, also in ALS studies. Thus, it is of utmost importance to relate outcome scores of both instruments to allow for comparison in ALS patients. This study reports on the performance of ALS patients in both tests with regard to incidence and degree of cognitive impairment, and the correspondence of both, ECAS and MMSE scores. Methods: We examined N = 84 ALS patients with the German versions of the ECAS and the MMSE. Performance in both tests regarding incidence and degree of cognitive impairment, and correspondence of frequency of cognitive impairment according to both tests was examined. The relationship between ECAS and MMSE scores was modelled with a non-linear regression model. Results: All ALS patients were able to complete the ECAS, 89.3% (N = 75) were capable to complete the MMSE. Prevalence of cognitive impairment was in both tests 22.7%, however agreement was only 52.9%. Despite, regression analyses yielded a strong positive relationship (adjusted R2 =.68) between the ECAS total score and the MMSE total score. Both tests were able to identify all patients with dementia. Conclusion: These results suggest that the MMSE is not ideal for cognitive screening in early-stage ALS patients. However, a rough translation of MMSE scores in ECAS scores is possible to estimate the cognitive performance level of patients, with the ECAS being more discriminative in the lower range of cognitive dysfunction (ECAS score: 80–136), for which the MMSE does not define cognitive impairment (corresponding MMSE score: 27–30). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Olfactory screening of Parkinson’s Disease patients and healthy subjects in China and Germany: A study of cross-cultural adaptation of the Sniffin’ Sticks 12-identification test

Author

Pinkhardt, Elmar H., primary, Liu, Huijing, additional, Ma, Di, additional, Chen, Jing, additional, Pachollek, Adrian, additional, Kunz, Martin S., additional, Kassubek, Jan, additional, Ludolph, Albert C., additional, Huang, Yining, additional, Chen, Haibo, additional, Landwehrmeyer, G. Bernhard, additional, Wang, Zhaoxia, additional, and Su, Wen, additional

Published
2019
Full Text
View/download PDF

5. Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE

Author

Payan, Christine A. M., Viallet, François, Agid, Yves, Ludolph, Albert C., Leigh, Peter N., Bensimon, Gilbert, NNIPPS Study Group, Landwehrmeyer, Bernhard Georg, Bonnet, Anne-Marie, Borg, Michel, Durif, Franck, Lacomblez, Lucette, Bloch, Frédéric, Verny, Marc, Fermanian, Jacques, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Immunologie - Immunopathologie - Immunothérapeutique (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier du Pays d'Aix, University of Ulm (UUlm), Fédération de neurologie 4, Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC AP-HP [CHU Pitié-Salpêtrière], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Pasteur [Nice] (CHU), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Laboratoire International de Neuroimagerie et Modélisation (Linem), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Montréal (UdeM)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Sussex, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and Univ Angers, Okina

Subjects
Psychometrics, [SDV]Life Sciences [q-bio], lcsh:Medicine, Limb dystonia, Social and Behavioral Sciences, Gastroenterology, Severity of Illness Index, 0302 clinical medicine, Psychology, lcsh:Science, Randomized Controlled Trials as Topic, Dystonia, Observer Variation, Multidisciplinary, Movement Disorders, Statistics, Neurodegenerative Diseases, Parkinson Disease, 3. Good health, [SDV] Life Sciences [q-bio], Neurology, RC0346, Disease Progression, Medicine, Supranuclear Palsy, Progressive, medicine.symptom, Research Article, Test Evaluation, medicine.medical_specialty, Drugs and Devices, Biology, Biostatistics, Progressive supranuclear palsy, 03 medical and health sciences, Atrophy, Neuropharmacology, Rating scale, Diagnostic Medicine, 030225 pediatrics, Internal medicine, Severity of illness, medicine, Humans, lcsh:R, Multiple System Atrophy, medicine.disease, nervous system diseases, Physical therapy, lcsh:Q, Myoclonus, 030217 neurology & neurosurgery, Mathematics
Abstract

PLoS one 6(8), e22293 (2011). doi:10.1371/journal.pone.0022293, Published by PLoS, Lawrence, Kan.

Published
2011

15. The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)

Author

Brettschneider, Johannes, primary, Czerwoniak, Anne, additional, Senel, Makbule, additional, Fang, Lubin, additional, Kassubek, Jan, additional, Pinkhardt, Elmar, additional, Lauda, Florian, additional, Kapfer, Tamara, additional, Jesse, Sarah, additional, Lehmensiek, Vera, additional, Ludolph, Albert C., additional, Otto, Markus, additional, and Tumani, Hayrettin, additional

Published
2010
Full Text
View/download PDF

17. A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis.

Author

Dupuis, Luc, Dengler, Reinhard, Heneka, Michael T., Meyer, Thomas, Zierz, Stephan, Kassubek, Jan, Fischer, Wilhelm, Steiner, Franziska, Lindauer, Eva, Otto, Markus, Dreyhaupt, Jens, Grehl, Torsten, Hermann, Andreas, Winkler, Andrea S., Bogdahn, Ulrich, Benecke, Reiner, Schrank, Bertold, Wessig, Carsten, Grosskreutz, Julian, and Ludolph, Albert C.

Abstract

Background: Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS). Methods/Principal Findings: We performed a phase II, double blind, multicentre, placebo controlled trial of pioglitazone in ALS patients under riluzole. 219 patients were randomly assigned to receive 45 mg/day of pioglitazone or placebo (one: one allocation ratio). The primary endpoint was survival. Secondary endpoints included incidence of non-invasive ventilation and tracheotomy, and slopes of ALS-FRS, slow vital capacity, and quality of life as assessed using EUROQoL EQ-5D. The study was conducted under a two-stage group sequential test, allowing to stop for futility or superiority after interim analysis. Shortly after interim analysis, 30 patients under pioglitazone and 24 patients under placebo had died. The trial was stopped for futility; the hazard ratio for primary endpoint was 1.21 (95% CI: 0.71-2.07, p = 0.48). Secondary endpoints were not modified by pioglitazone treatment. Pioglitazone was well tolerated. Conclusion/Significance: Pioglitazone has no beneficial effects on the survival of ALS patients as add-on therapy to riluzole.Trial Registration: Clinicaltrials.gov NCT00690118. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results